Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 August 2023 | Story Andre Damons | Photo Andre Damons
Dr Kgomotso Moroka
Dr Kgomotso Moroka, Acting HOD: Cardiology in the UFS Faculty of Health Sciences, recently graduated from Maastricht University with a Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM).

A staff member from the University of the Free State (UFS) is hopeful her newly acquired skills and knowledge, following her graduation with a Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM) and completion of a electrophysiology fellowship, will contribute to the improvement of cardiovascular services in the Free State and Sub-Saharan Africa.

Dr Kgomotso Moroka, the Acting Head of Department (HOD) for Cardiology in the UFS Faculty of Health Sciences, recently graduated with a DAS-CAM in June 2023. This distinctive postgraduate programme is offered by Maastricht University in collaboration with the European Heart Rhythm Association and the European Society of Cardiology. This is a two-year programme and Dr Moroka was part of the third cohort which comprised 32 electrophysiologists selected from over 20 countries worldwide.

Her achievement places her as the sole   DAS-CAM graduate in Sub-Saharan Africa and the Free State region. 
Electrophysiology, which studies the electrical influences and patterns of the heart is vital for treating patients with abnormal heartbeats caused by irregularities in the heart’s electrical pathway, resulting in either unusually slow or fast heartbeats.

Seizing a valuable opportunity

Dr Moroka emphasises that currently, there is a lack of electrophysiology services provided in both the public and private sectors within the Free State. She therefore anticipates that her newly acquired skills and knowledge will play a pivotal role in enhancing and improving the cardiovascular services offered in the province. She is also optimistic about contributing to the establishment of a department dedicated to Electrophysiology Training. 

“I could not pass up the opportunity to engage with, learn and gain insights from seasoned world-class great minds of electrophysiology, who write the books we read and the very guidelines that we utilize in our daily practices. There was also an opportunity to be guided in research and the state-of-the-art cardiac clinical electrophysiology while also obtaining insights into how to develop a cardiac arrhythmia centre, biostatics, health economics, leadership skills and health technology assessment,” Dr Moroka explains regarding her motivation to enrol in the program. 

“It was a challenging and exciting program that allowed participants to engage with the world-renowned experts in electrophysiology not only on a professional but also personal level. This program served not only to educate participants on clinical cardiac electrophysiology but served to empower us to fulfil roles as future leaders in electrophysiology and in our day-to-day roles,” she continued.

Addressing the diverse burden of cardiac diseases

Dr Moroka believes that this qualification will significantly contribute to local efforts to establish and develop a much-needed unique service, thereby advancing her career development locally and on the international platform. This qualification enables her to expand her clinical research pursuits on multiple fronts.

Dr Moroka underscores the substantial burden of ischemic heart disease with the associated risk factors such as uncontrolled high blood pressure, diabetes, elevated cholesterol levels and smoking. “There is a measurable burden of heart failure and valvular heart disease. In addition, from the research that we hope to embark upon, we hope to clearly define the burden of rhythm problems such as atrial fibrillation and other arrhythmias which are serious conditions. With the available skills and knowledge, we can begin to offer alternative adjunctive treatment that would have a significant positive effect on the morbidity and/or mortality of our patients.”

Dr Moroka points out that with the advent and advances in machine learning and digital health technology, we are in an exciting era of possibilities of obtaining valuable biological data and biometric parameters that would assist in the reduction of risk and prevention of a diversity of cardiovascular diseases and to guide clinical practice guidelines. 

“The current focus is risk reduction, prevention of cardiovascular diseases and the establishment and development of personalized health care, with a growing interest in cardiovascular genetics and gene therapy.  Who knows what the future will bring, but for now the focus is to work towards good health and disease alleviation,” she says. 

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept